# A Study of Osimertinib-based Adaptive Treatment Guided by ctDNA EGFRm+ Monitoring in NSCLC

> **NCT07058519** · PHASE2 · RECRUITING · sponsor: **Shanghai Chest Hospital** · enrollment: 250 (estimated)

## Conditions studied

- Locally Advanced or Metastatic EGFRm Non-small Cell Lung Cancer (NSCLC)

## Interventions

- **DRUG:** Osimertinib-based adaptive treatment
- **DRUG:** Osimertinib 80 MG

## Key facts

- **NCT ID:** NCT07058519
- **Lead sponsor:** Shanghai Chest Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-23
- **Primary completion:** 2029-01-24
- **Final completion:** 2029-01-24
- **Target enrollment:** 250 (ESTIMATED)
- **Last updated:** 2025-11-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07058519

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07058519, "A Study of Osimertinib-based Adaptive Treatment Guided by ctDNA EGFRm+ Monitoring in NSCLC". Retrieved via AI Analytics 2026-07-22 from https://api.ai-analytics.org/clinical/NCT07058519. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*